Clinical trials: Motor Neuron Disorder
Motor Disorders
Patients With ALS and Other Motor Disorders Will be Treated With Umbilical or Placental Mesenchymal Cell Exosome Solution
Patients with ALS and other Motor Discorders will be treated with mesenchymal cell exosome solution.
- Trial name
- NCT07105371
- Testing
- Exosome Secretome
- Where
- 2 sites in United States, Greece
- Volunteers
- 70 people
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
Bulbar Palsy
The Effectiveness of Stellate Ganglion Block in Managing Dysphagia in Patients With Medullary Infarction
This is a randomized controlled study, including dysphagic patients with bulbar palsy after ischemic stroke who were received in the department of rehabilitation medicine.
- Trial name
- NCT06301698
- Testing
- Comprehensive rehabilitation, Injection, Lidocaine Hydrochloride
- Volunteers
- 80 people
- Sponsor
- Ahmadu Bello University Teaching Hospital
Spinal Muscular Atrophy
A Registered Cohort Study on SMA
Spinal muscular atrophy (SMA) is an autosomal recessive disease that causes progressive muscle wasting and weakness due to loss of motor neurons in the spinal cord.
- Trial name
- NCT04010604
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Wan-Jin Chen
ALS (Amyotrophic Lateral Sclerosis), Postpoliomyelitis Syndrome
Impairments of Neuro-muscular Communication in Motor-Neuron Disease: A Bio-Marker for Early and Personalised Diagnosis
Motor neuron disease (MND) or ALS is a nervous system disease. ALS leads to a loss of movement ability that eventually leads to death. At the moment, there is no known treatment for ALS.
- Conditions
- ALS (Amyotrophic Lateral Sclerosis), Postpoliomyelitis Syndrome, Spinal Muscular Atrophy
- Trial name
- MotorMarker (NCT05663008)
- Testing
- 128 electrode electroencephalography (EEG), Bipolar surface electromyography (sEMG), High-density electromyography (HD-EMG)
- Where
- Ireland
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University of Dublin, Trinity College
C9orf72 Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia
Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD
The primary objective is to assess the safety and tolerability of Metformin in subjects with C9orf72 amyotrophic lateral sclerosis administered for 24 weeks.
- Trial name
- NCT04220021
- Testing
- Metformin
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Florida
Amyotrophic Lateral Sclerosis
Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation
The purposes of the study are to determine the energy balance and evaluate the nutritional status of patients with ALS, and to investigate the use of NIPPV as respiratory support to treat patients with ALS.
- Trial name
- NCT00116558
- Testing
- Early NIPPV, Standard NIPPV
- Where
- 12 sites in United States
- Volunteers
- 153 people
- Sponsor
- Edward Kasaraskis
Muscular Atrophy, Spinal
Pediatric Spinal Muscular Atrophy (SMA) China Registry
The primary objective of the study is to describe the natural history and utilization of disease modifying therapy (DMT) treatments among pediatric Chinese participants with spinal muscular atrophy linked to chromosome 5q…
- Trial name
- NCT05042921
- Where
- 25 sites in China
- Volunteers
- 600 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis
Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation
This study evaluates NP001 in patients with amyotrophic lateral sclerosis (ALS) and evidence of systemic inflammation. Half of participants will receive NP001 and the other half will receive placebo.
- Trial name
- NCT02794857
- Testing
- NP001
- Where
- 22 sites in United States, Canada
- Volunteers
- 138 people
- Sponsor
- Neuraltus Pharmaceuticals, Inc.
Amyotrophic Lateral Sclerosis
Cistanche Total Glycosides for Amyotrophic Lateral Sclerosis: A Randomized Control Trial (RCT) Study Assessing Clinical Response
This study will examine the effectiveness of Cistanche Total Glycosides(CTG) in treating patients with amyotrophic lateral sclerosis (ALS) - a fatal neurological degenerative disease that causes adult-onset, progressive motor…
- Trial name
- NCT00753571
- Testing
- Cistanche Total Glycosides
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University
Infantile Spinal Muscular Atrophy, Type I [Werdnig- Hoffman]
Allogeneic Adipose Derived Stem Cells for Werdnig Hoffman Patients
Spinal Muscular Atrophy (SMA) is an autosomal recessive disease of motor neurons. In the early 1980s, Werdnig from Vienna University and Hoffman from Heidelberg University described this disorder.
- Trial name
- NCT02855112
- Testing
- Adipose derived mesenchymal stem cell
- Where
- Iran
- Volunteers
- 10 people
- Sponsor
- Tehran University of Medical Sciences
ALS - Amyotrophic Lateral Sclerosis
Comprehensive Biomarker Profiling of the IFN-α Pathway in Amyotrophic Lateral Sclerosis Patient Biofluids
ALS is characterized by significant genetic, clinical, and biological heterogeneity. The heritability of ALS is approximately 50%, and variants in more than 200 genes have been associated with the disease.
- Trial name
- NCT07260981
- Where
- Ireland
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ulysses Neuroscience LTD
Muscular Atrophy, Spinal
A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)
In this study, researchers will learn more about the use of nusinersen (BIIB058) in participants with spinal muscular atrophy (SMA).
- Trial name
- ONWARD (NCT04729907)
- Testing
- Nusinersen
- Where
- 39 sites in United States, Brazil and 14 more
- Volunteers
- 115 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis
Spinal Cord Associative Plasticity for ALS
Veterans are at higher risk than non-Veterans of falling ill with amyotrophic lateral sclerosis (ALS). The investigators have shown that synchronized stimulation over the brain and cervical spinal cord can temporarily strengthen…
- Trial name
- NCT06172621
- Testing
- Spinal Cord Associative Plasticity (SCAP), Upper extremity task-oriented exercise
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- VA Office of Research and Development
Cerebral Palsy (CP)
Effects of Motor Imagery and Action Observation on Motor Function in Unilateral Cerebral Palsy
The aim of this study is to evaluate the effects of action observation therapy and motor imagery methods, provided in addition to a conventional physiotherapy and rehabilitation program, on gross motor function, upper and lower…
- Trial name
- NCT07612371
- Testing
- motor imagery, Action observation therapy, Conventional physiotherapy group
- Where
- Turkey (Türkiye)
- Volunteers
- 48 people
- Sponsor
- Bahçeşehir University
Amyotrophic Lateral Sclerosis
Salivary Biomarker Discovery by Raman Spectroscopy in ALS (SalivALS)
BACKGROUND/RATIONALE: The paucity of biomarkers for the diagnosis and monitoring of patients affected by Amyotrophic Lateral Sclerosis (ALS) is one of the greatest concerns in ALS clinics and research.
- Trial name
- SalivALS (NCT04233099)
- Testing
- Raman analysis of saliva with data collection and analysis
- Where
- 2 sites in Italy
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Fondazione Don Carlo Gnocchi ETS
Amyotrophic Lateral Sclerosis
Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to compare the effectiveness of lithium combined with riluzole to riluzole combined with placebo in people with amyotrophic lateral sclerosis.
- Trial name
- NCT00818389
- Testing
- Lithium Carbonate, Riluzole
- Where
- 37 sites in United States, Canada
- Volunteers
- 84 people
- Sponsor
- Massachusetts General Hospital
Cystinosis, Cystinosis, Nephropathic
Genetic Newborn Screening for Cystinosis and Spinal Muscular Atrophy
Newborn screening in Germany is a voluntary program. Cystinosis and spinal muscular atrophy (SMA) are rare autosomal recessive diseases. They are inherited in an autosomal recessive manner, i.e.
- Conditions
- Cystinosis, Cystinosis, Nephropathic, Spinal Muscular Atrophy
- Trial name
- GENESIS1 (NCT06027385)
- Testing
- molecular-based screening
- Where
- 4 sites in Germany
- Volunteers
- 300,000 people
- Sponsor
- Cystinose Stiftung
Amyotrophic Lateral Sclerosis, Nervous System Diseases
A Longitudinal Study of Amyotrophic Lateral Sclerosis (ALS) Biomarkers
The purpose of this study is to collect biofluid samples for the banking and usage in ALS research. Through comparison of these samples, the researchers hope to learn more about the underlying cause of ALS, as well as find unique…
- Conditions
- Amyotrophic Lateral Sclerosis, Nervous System Diseases, Sclerosis, Motor Neuron Disease
- Trial name
- NCT01495390
- Where
- 6 sites in United States
- Volunteers
- 139 people
- Sponsor
- Massachusetts General Hospital
Amyotrophic Lateral Sclerosis
Confirmation of Self-Reported Incident ALS Cases in the AARP-Diet and Health (AARP-DH) Cohort
Amyotrophic Lateral Sclerosis (ALS) is a rare but rapidly progressive neurological disease that often results in death within a few years after the diagnosis.
- Trial name
- NCT00377351
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Amyotrophic Lateral Sclerosis, Adenosine Triphosphate Activities
Effect of Terazosin on ATP Levels in People With Amyotrophic Lateral Sclerosis
This will be a single center, randomized, double-blind, placebo-controlled pilot study to assess the safety and tolerability of terazosin (TZ) at a dose of 5 milligrams (mg) per os (PO) daily for patients with amyotrophic lateral…
- Trial name
- TZ-ALS (NCT07224269)
- Testing
- Terazosine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Iowa